{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".78","upperLimit":".84","value":".81"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Amount of agreement among the 11 blinded head and neck cancer specialists, determined by the Fleiss Kappa. 33 benign and 65 cancer images were evaluated by the reviewers who were blinded to the anatomical site, tumor subsite, and final histopathologic diagnosis. Each reviewer was asked to classify each image as benign or neoplastic. The reviewers evaluated the images based on nuclear size, nuclear to cytoplasmic ratio, and overall cell architecture. Images were randomized in their presentation to the reviewers as to not establish any pattern. Each reviewer provided their interpretation in isolated settings to avoid influence from other reviewers.","dispersionType":"95% Confidence Interval","groups":[{"description":"High Resolution Microendoscopy (HRME) imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer. 0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa. HRME is used to capture images of suspicious areas sprayed with proflavine hemisulfate.","id":"OG000","title":"HRME With Proflavine"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Immediately following image (day of enrollment or up to 2 weeks after enrollment)","title":"Interrater Reliability","type":"PRIMARY","unitOfMeasure":"proportion of agreement among 11 experts"}